搜索
吉利德科学
GILD添加自选
131.330USD
-2.730-2.04%
收盘 05/08, 16:00（美东）报价延迟15分钟
163.06B总市值
17.72市盈率 TTM
查看详细走势图
盘中分时
1分
30分
1小时
日k
周k
月k
日k
今天
-2.04%
5天
-0.24%
1月
-5.51%
6月
+11.16%
今年开始到现在
+7.00%
1年
+35.52%
TradingKey 吉利德科学股票评分
单位: USD 更新时间: 2026-05-08操作建议
吉利德科学当前公司基本面数据相对健康，最新ESG披露属于行业领先水平。增长潜力很大。当前估值合理，在药品行业排名10/156位。机构持股占比非常高，近一月多位分析师给出公司评级为买入。最高目标价158.83。中期看，股价处于下降通道。近一个月，市场表现较差，但公司基本面和技术面得分较高。目前股价在压力位和支撑位之间，可以做区间波段操作。
吉利德科学评分
压力支撑
由于公司未披露，未能获取相关数据
多维评测
本期评分
上期评分
公司舆情
过去24小时
热度
过冷
过热
极度看好
吉利德科学亮点
亮点风险
Gilead Sciences, Inc. is a biopharmaceutical company. It is engaged in advancing medicines to prevent and treat life-threatening diseases, including HIV, viral hepatitis, COVID-19, cancer and inflammation. It is focused on discovering, developing and delivering medicines to address unmet medical needs in virology, oncology and other therapeutic areas. Its portfolio of marketed products includes Biktarvy, Genvoya, Descovy, Complera/Eviplera, Symtuza, Truvada, Stribild, Sunlenca, Epclusa, Vemlidy, Harvoni, Viread, Livdelzi, Veklury, Yescarta, Tecartus, Trodelvy, AmBisome, and Letairis. Its product candidates include Bulevirtide, Lenacapavir, Axicabtagene ciloleucel, Sacituzumab govitecan-hziy, and others. It also develops the HB-400 program and the HB-500 program. It develops therapies that are intended to provide functional cures for hepatitis B virus and human immunodeficiency virus-1. It operates in more than 35 countries worldwide.
利润高增长
公司净利润处于行业前列，最新年度总收入29.44B美元
高分红
公司属于高分红公司，最新股息支付率814.79%
稳定分红
公司5年内连续分红，最新股息支付率814.79%
估值低估
公司最新PE估值17.72，处于3年历史低位
机构加仓
最新机构持股1.15B股，环比增加0.18%
Mairs and Power 公司持仓
明星投资者Mairs and Power 公司持仓，最新持仓市值15.38K
分析师目标
根据
33
位分析师
买入
评级
158.794
目标均价
+18.45%
涨幅空间
数据免责声明：分析师评级与目标价由LSEG提供，仅供参考，不应当作投资建议
财务指标
每股收益
由于公司未披露，未能获取相关数据
营业总收入
由于公司未披露，未能获取相关数据
吉利德科学简介
Gilead Sciences, Inc. is a biopharmaceutical company. It is engaged in advancing medicines to prevent and treat life-threatening diseases, including HIV, viral hepatitis, COVID-19, cancer and inflammation. It is focused on discovering, developing and delivering medicines to address unmet medical needs in virology, oncology and other therapeutic areas. Its portfolio of marketed products includes Biktarvy, Genvoya, Descovy, Complera/Eviplera, Symtuza, Truvada, Stribild, Sunlenca, Epclusa, Vemlidy, Harvoni, Viread, Livdelzi, Veklury, Yescarta, Tecartus, Trodelvy, AmBisome, and Letairis. Its product candidates include Bulevirtide, Lenacapavir, Axicabtagene ciloleucel, Sacituzumab govitecan-hziy, and others. It also develops the HB-400 program and the HB-500 program. It develops therapies that are intended to provide functional cures for hepatitis B virus and human immunodeficiency virus-1. It operates in more than 35 countries worldwide.
公司代码GILD
公司吉利德科学
CEOO'Day (Daniel P)
网址https://www.gilead.com/
相关品种
